REFERENCES
- Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activ-ity. Antimicrob Agents Chemother 2005;49:4721–4732.
- Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429–1441.
- Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010;201:803–813.
- ViiV Healthcare. Celsentri (maraviroc) summary of product characteristics. December 15, 2011. http://www.viivhealthcare.com/products/selzentry-celsentri.aspx#. Accessed 2012.
- European Medicines Agency. Celsentri: summary of product characteristics. December 7, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000811/WC500022190.pdf. Accessed April 19,2011.
- Abel S, Russell D, Whitlock LA, et al. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmaco. 2008;65\(suppl 1):60–67.
- Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos. 2005;33:587–595.
- Hyland R, Dickins M, Collins C, et al. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol. 2008;66:498–507.
- Weatherley B, McFadyen L. Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model. Br J Clin Pharmaco. 2009;68:355–369.
- Huang SM, Temple R, Xiao S, et al. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharmacol Ther. 2009;86:475–479.
- Abel S, Russell D, Taylor-Worth RJ, et al. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmaco. 2008;65 (suppl 1):27–37.
- de Silva TI, Post FA, Griffin MD, et al. HIV-1 infection and the kidney: an evolving challenge in HIV medicine. Mayo Clin Proc. 2007;82:1103–1116.
- Post FA, Holt SG. Recent developments in HIV and the kidney. Curr Opin Infect Dis. 2009;22:43–48.
- Abel S, Davis JD, Ridgway CE, et al. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. Antivir Ther. 2009;14:831–837.
- Abel S, Jenkins TM, Whitlock LA, et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmaco. 2008;65\(suppl 1):38–46.
- US Food and Drug Administration. Selzentry: prescribing information. 2011. http://media.pfizer.com/files/products/uspi_maraviroc.pdf. Accessed April 19, 2011.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
- US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research et al. Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis and impact on dosing and labelling. 2011. http://www.fda.gov/downloads/Drugs/GuidanceCompli-anceRegulatoryInformation/Guidances/UCM072127.pdf. Accessed April 19, 2011.
- Brewer E, Felix T, Clarke P, et al. An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857) in human plasma, urine and cerebrospinal fluid. Biomed Chromatogr 2010;24:1316–1323.
- Dreisbach AW. The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther. 2009;86:553–556.
- US Food and Drug Administration. Crestor: prescribing information. November 1,2010. http://www.crestor.com/c/home.aspx. Accessed April 19, 2011.
- Lalonde RL, Wagner JA. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment. Clin Pharmacol Ther. 2009;86:557–561.
- McFadyen L, Weatherley B, Vourvahis M. Population modelling of maraviroc pharmacokinetic data when administered with and without saquinavir/ritonavir in subjects with renal dysfunction. Poster presented at: 11th International Workshop on the Clinical Pharmacology of HIV Therapy; April 7–9, 2010; Sorrento, Italy.